Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Nineteen Twenty-One is a venture capital firm founded by Fredrik Debong and based in Vienna, Austria. The firm has an $11 million fund and focuses on early-stage investments in healthcare and biotech sectors. It is particularly interested in solutions for type 1 diabetes and associated health issues.
Nineteen Twenty-One invests between $200K and $1M in pre-seed to seed+ stage companies. The firm targets startups that develop technology-enabled or biology-driven solutions for type 1 diabetes and related conditions, including cardiovascular and metabolic diseases.
Submit your pitch through their form at 1921.vc or email your deck to fred@1921.vc.
Yes, Nineteen Twenty-One often leads investment rounds in the companies they support, particularly in the early stages.
The firm is open to follow-on investments, especially for companies that align with their focus on type 1 diabetes solutions.
Nineteen Twenty-One currently manages an $11 million fund dedicated to early-stage healthcare and biotech investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.